710348-76-8

Upstream product

• 710348-75-7 methyl 3-chloro-2-oxo-5-phenylpentanoate 
• 17356-08-0 thiourea 
• 104-53-0 3-phenyl-propionaldehyde 
• 67-56-1 methanol 
• 535-15-9 ethyl 1,1-dichloroacetate 

Downstream Products

• 864437-48-9 5-phenethyl-thiazole-4-carboxylic acid 
• 1453101-98-8 2-(2-acetamido-5-isopropylthiazole-4-carboxamido)-5-phenethylthiazole-4-carboxylic acid 
• 1453101-99-9 2-acetamido-N-(4-((3-(dimethylamino)propyl)carbamoyl)-5-phenethylthiazol-2-yl)-5-isopropylthiazole-4-carboxamide 
• 1453101-97-7 methyl 2-(2-acetamido-5-isopropylthiazole-4-carboxamido)-5-phenethylthiazole-4-carboxylate 

Relevant academic research and scientific papers

Identification of potent type I MetAP inhibitors by simple bioisosteric replacement. Part 1: Synthesis and preliminary SAR studies of thiazole-4-carboxylic acid thiazol-2-ylamide derivatives

A series of thiazole-4-carboxylic acid thiazol-2-ylamide (TCAT, 4) derivatives were designed and synthesized according to simple bioisosteric replacement from previously reported pyridine-2-carboxylic acid thiazol-2-ylamide (PCAT) MetAP inhibitors. The preliminary SAR studies demonstrated that these TCAT series of compounds showed different activity and selectivity compared with those of the corresponding PCAT compounds. These findings provide useful information for the design and discovery of more potent inhibitors of type I MetAPs.

TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).